Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | RORC | P51449 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1943497 | 0.83 | HRH3 (0.75) | HRH3KMT2AMEN1ATMCYP2D6 | |
| SCHEMBL188249 | 0.83 | KMT2A (0.54) | HRH3KMT2AMEN1ATMALDH1A1 | |
| SCHEMBL188521 | 0.83 | ALDH1A1 (0.54) | HRH3KMT2AMEN1ATMTSHR | |
| SCHEMBL2978762 | 0.81 | HRH3 (0.59) | HRH3KMT2AMEN1ATMCYP2D6 | |
| SCHEMBL321890 | 0.81 | HRH3 (0.78) | HRH3KMT2AMEN1ATMCYP2D6 | |
| SCHEMBL3239820 | 0.81 | HRH3 (0.78) | HRH3KMT2AMEN1ATMCYP2D6 | |
| SCHEMBL29056068 | 0.81 | HRH3 (0.78) | HRH3KMT2AMEN1ATMCYP2D6 | |
| SCHEMBL8122521 | 0.81 | HRH3 (0.78) | HRH3KMT2AMEN1ATMCYP2D6 | |
| SCHEMBL27879358 | 0.80 | MEN1 (0.59) | HRH3KMT2AMEN1ATMCYP2D6 | |
| SCHEMBL27862081 | 0.80 | VEGFA (0.53) | HRH3KMT2AMEN1L3MBTL1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130237520-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-12 | — | — | US | claimed |
| EP-2373169-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-09-02 | — | — | US | claimed |
| WO-2010068257-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | SYROS PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS INC (US) | 2021-05-20 | — | — | US | disclosed |
| CN-112368285-A | Pyrrolotriazine compounds and methods of inhibiting TAM kinase | 希洛斯医药品股份有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-20200317676-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| EP-3694860-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | Syros Pharmaceuticals, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019074962-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS, INC. (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2018-03-29 | — | — | US | disclosed |
| US-9796718-B2 | 6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine | GILEAD CONNECTICUT, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-1423391-B8 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| EP-1423391-B1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050277627-A1 | Colchinol derivatives as vascular damaging agents | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2005-12-15 | — | — | US | disclosed |
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2005-03-10 | — | — | US | disclosed |
| EP-1423391-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | Novartis AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| EP-1301497-A1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | Angiogene Pharmaceuticals Limited (GB) | 2003-04-16 | — | — | EP | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
| WO-2002004434-A1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | CTSK, CTSS, CTSZ | HRH3 3056/4885KMT2A 4486/4885MEN1 4225/4885 |
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | PLK2, MAP3K5, CAMKK2 | HRH3 1973/4885KMT2A 691/4885MEN1 2739/4885 |
| US-20200317676-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | PLK2, MAP3K5, CAMKK2 | HRH3 1973/4885KMT2A 691/4885MEN1 2739/4885 |
| US-20130237520-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HRH3 1483/4885KMT2A 1035/4885MEN1 4290/4885 |
| US-20050277627-A1 | Colchinol derivatives as vascular damaging agents | TOP1, TDP1, TOP2B | HRH3 3669/4885KMT2A 4442/4885MEN1 1207/4885 |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | PLK2, MAP3K5, CAMKK2 | HRH3 1973/4885KMT2A 691/4885MEN1 2739/4885 |
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HRH3 1483/4885KMT2A 1035/4885MEN1 4290/4885 |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HRH3 1483/4885KMT2A 1035/4885MEN1 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.